Joint statement offers new recommendations for treating cardiovascular conditions
the ONA take:
A new scientific statement issued jointly by the American Heart Association, American College of Cardiology, and American Society of Hypertension addresses treatment goals for patients with high blood pressure who also have vascular diseases.
The statement acknowledges that a target blood pressure of less than 140/90 mm Hg is reasonable to reduce the risk of heart attacks and strokes in the general population, a lower target of less than 130/80 mm Hg may be appropriate for some patients with heart disease who have already experienced a stroke, heart attack, or mini-stroke (transient ischemic attack [TIA]).
Additional recommendations and contraindications include which antihypertensives to use in patients with various types of heart disease. The statement also recommends lowering blood pressure slowly in patients with coronary artery blockages.
Furthermore, clinicians should not strive to lower the diastolic number to less than 60 mm Hg, especially in patients older than 60 years.
These recommendations also reiterate the importance of modifying other risk factors, including abdominal obesity, abnormal cholesterol, diabetes, and smoking.
New statement addresses treatment goals for patients with high blood pressure who also have vascular diseases.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|